Late cardiac events after allogeneic stem cell transplant: incidence, risk factors, and impact on overall survival

被引:10
作者
Auberle, Christine [1 ]
Lenihan, Daniel [2 ,3 ]
Gao, Feng [1 ]
Cashen, Amanda [1 ]
机构
[1] Washington Univ, Sch Med, 660 South Euclid Ave,Box 8056, St Louis, MO 63110 USA
[2] Int Cardiooncol Soc, Tampa, FL USA
[3] St Francis Healthcare, Cape Girardeau, MO USA
关键词
Allogeneic stem cell transplant; Late cardiac events; Outcomes; BONE-MARROW-TRANSPLANTATION; CONGESTIVE-HEART-FAILURE; LONG-TERM SURVIVORS; REDUCED-INTENSITY; CARDIOVASCULAR-DISEASE; WORKING PARTY; LATE DEATHS; COMPLICATIONS; HYPERTENSION; PREDICTORS;
D O I
10.1186/s40959-022-00150-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background There is limited data on the impact of cardiac disease on long term outcomes of allogeneic stem cell transplant (alloSCT). Our study aims to describe the incidence of late cardiac events after alloSCT, identify risk factors for developing a late cardiac event, and illustrate the impact of late cardiac events on overall survival.Methods Patients who underwent alloSCT from 2007 to 2017 and survived more than 1 year after transplant (N = 804) were included. Gray's sub-distribution methods, while accounting for death as a competing risk, were used to calculate the cumulative incidence of late cardiac events. Univariate regression models based on Gray's sub-distribution were fitted to assess the potential predictive effects of baseline characteristics on the risk of developing any late cardiac events. Univariate Cox proportional hazard regression models were used to evaluate the association between late cardiac events and overall survival.Results The cumulative incidence of a late cardiac event at 5 years after transplant was 22% (95% CI 19-25%). The most frequent cardiac event was a decline in LVEF to < 45% with a cumulative incidence of 9% (95% CI 7-11%). Patients were at significantly increased hazard of developing a late cardiac event if they had a history of congestive heart failure prior to alloSCT (HR 4.53, 95% CI 2.57-7.97, p-value < 0.001), a decline in LVEF to < 45% (HR 3.95, 95% CI 2.09-7.47, p-value < 0.001) or cerebral vascular accident (HR 3.13, 95% CI 1.38-7.06, p-value 0.004). Transplant characteristics such as primary disease, donor type, use of TBI, myeloablative conditioning regimen or tyrosine kinase inhibitor had no significant association with late cardiac events. Almost all cardiac events demonstrated a significantly increased risk of death. This hazard was the highest in patients who experienced an atrial arrhythmia (HR 10.6, 95% CI 7.7-14.6).Conclusion Adverse cardiac events are relatively common late after alloSCT with identifiable risk factors such as medical comorbidities prior to transplant and are associated with a negative impact on overall survival.
引用
收藏
页数:8
相关论文
共 31 条
[1]   Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT) [J].
Aoudjhane, M ;
Labopin, M ;
Gorin, NC ;
Shimoni, A ;
Ruutu, T ;
Kolb, HJ ;
Frassoni, F ;
Boiron, JM ;
Yin, JL ;
Finke, J ;
Shouten, H ;
Blaise, D ;
Falda, M ;
Fauser, AA ;
Esteve, J ;
Polge, E ;
Slavin, S ;
Niederwieser, D ;
Nagler, A ;
Rocha, V .
LEUKEMIA, 2005, 19 (12) :2304-2312
[2]   National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Cardiovascular Disease and Associated Risk Factors Working Group Report [J].
Armenian, Saro H. ;
Chemaitilly, Wassim ;
Chen, Marcus ;
Chow, Eric J. ;
Duncan, Christine N. ;
Jones, Lee W. ;
Pulsipher, Michael A. ;
Remaley, Alan T. ;
Rovo, Alicia ;
Salooja, Nina ;
Battiwalla, Minoo .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (02) :201-210
[3]   Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease [J].
Armenian, Saro H. ;
Sun, Can-Lan ;
Vase, Tabitha ;
Ness, Kirsten K. ;
Blum, Emily ;
Francisco, Liton ;
Venkataraman, Kalyanasundaram ;
Samoa, Raynald ;
Wong, F. Lennie ;
Forman, Stephen J. ;
Bhatia, Smita .
BLOOD, 2012, 120 (23) :4505-4512
[4]   Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation [J].
Armenian, Saro H. ;
Sun, Can-Lan ;
Shannon, Tabitha ;
Mills, George ;
Francisco, Liton ;
Venkataraman, Kalyanasundaram ;
Wong, F. Lennie ;
Forman, Stephen J. ;
Bhatia, Smita .
BLOOD, 2011, 118 (23) :6023-6029
[5]   Predictors of Late Cardiovascular Complications in Survivors of Hematopoietic Cell Transplantation [J].
Armenian, Saro H. ;
Sun, Can-Lan ;
Mills, George ;
Teh, Jennifer Berano ;
Francisco, Liton ;
Durand, Jean-Bernard ;
Wong, F. Lennie ;
Forman, Stephen J. ;
Bhatia, Smita .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (08) :1138-1144
[6]   Late Congestive Heart Failure After Hematopoietic Cell Transplantation [J].
Armenian, Saro H. ;
Sun, Can-Lan ;
Francisco, Liton ;
Steinberger, Julia ;
Kurian, Seira ;
Wong, F. Lennie ;
Sharp, Jon ;
Sposto, Richard ;
Forman, Stephen J. ;
Bhatia, Smita .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (34) :5537-5543
[7]   Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study [J].
Baker, K. Scott ;
Ness, Kirsten K. ;
Steinberger, Julia ;
Carter, Andrea ;
Francisco, Liton ;
Burns, Linda J. ;
Sklar, Charles ;
Forman, Stephen ;
Weisdorf, Daniel ;
Gurney, James G. ;
Bhatia, Smita .
BLOOD, 2007, 109 (04) :1765-1772
[8]   Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study [J].
Bhatia, Smita ;
Francisco, Liton ;
Carter, Andrea ;
Sun, Can-Lan ;
Baker, K. Scoff ;
Gurney, James G. ;
McGlave, Philip B. ;
Nademanee, Auayporn ;
O'Donnell, Margaret ;
Ramsay, Norma K. C. ;
Robison, Leslie L. ;
Snyder, David ;
Stein, Anthony ;
Forman, Stephen J. ;
Weisdorf, Daniel J. .
BLOOD, 2007, 110 (10) :3784-3792
[9]   Cancer patients with markedly elevated B-type natriuretic peptide may not have volume overload [J].
Burjonroppa, Sukesh C. ;
Tong, Ann T. ;
Xiao, Lian-Chun ;
Johnson, Marcella M. ;
Yusuf, S. Wamique ;
Lenihan, Daniel J. .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2007, 30 (03) :287-293
[10]  
CAZIN B, 1986, CANCER-AM CANCER SOC, V57, P2061, DOI 10.1002/1097-0142(19860515)57:10<2061::AID-CNCR2820571031>3.0.CO